The cost-utility of haemodiafiltration versus haemodialysis in the convective transport study

Nephrology Dialysis Transplantation

Volumn 28, Issue 7, 2013, Pages 1865-1873

  Mazairac, Albert H A ^a   Blankestijn, Peter J ^a   Grooteman, Muriel P C ^b,c   Lars Penne, E ^a,b   Van Der Weerd, Neelke C ^a,b   Den Hoedt, Claire H ^a,d   Buskens, Erik ^e   Van Den Dorpel, Marinus A ^d   Ter Wee, Piet M ^b,c   Nubé, Menso J ^b,c   Bots, Michiel L ^a   Ardine De Wit, G ^a,f  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Maasstad Hospital Rotterdam   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Cost utility analysis; Haemodiafiltration; Haemodialysis

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEMODIAFILTRATION; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS;

COST-UTILITY ANALYSIS; HAEMODIAFILTRATION; HAEMODIALYSIS;

AGED; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMODIAFILTRATION; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL RATE;

EID: 84874623343     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft045     Document Type: Article

References (35)

1. Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health 2009; 12: 80-87
2. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010
3. Mazairac AH, de Wit GA, Penne EL et al. Changes in quality of life over time-Dutch haemodialysis patients and general population compared. Nephrol Dial Transplant 2011; 26: 1984-1989
4. Gorodetskaya I, Zenios S, McCulloch CE et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005; 68: 2801-2808
5. Just PM, Riella MC, Tschosik EA et al. Economic evaluations of dialysis treatment modalities. Health Policy 2008; 86: 163-180
6. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998; 44: 215-232
7. McFarlane PA, Bayoumi AM, Pierratos A et al. The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int 2003; 64: 1004-1011
8. Gonzalez-Perez JG, Vale L, Stearns SC et al. Hemodialysis for end-stage renal disease: a cost-effectiveness analysis of treatmentoptions. Int J Technol Assess Health Care 2005; 21: 32-39
9. Haller M, Gutjahr G, Kramar R et al. Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol Dial Transplant 2011; 29: 2988-2995
10. den Hoedt CH, Mazairac AHA, Dorpel MA et al. The effect of hemodiafiltration on mortality, inflammation and quality of life. In: Kawanishi H, Yamashita AC (eds). Hemodiafiltration-A New Era. Basel: Karger, 2010, pp. 39-52
11. Grooteman MP, van den Dorpel MA, Bots ML et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012; 23: 1087-1096
12. Ok E, Asci G, Ok ES et al. Comparison of Postdilution Online Hemodiafiltration and Hemodialysis (Turkish HDF Study). XLVIII ERA-EDTA Congress 2011, Prague, Chech Republic, 2011
13. Penne EL, Blankestijn PJ, Bots ML et al. Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients-the Dutch CONvective TRAnsport STudy (CONTRAST): rationale and design of a randomised controlled trial [ISRCTN38365125]. Curr Control Trials Cardiovasc Med 2005; 6: 8
14. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. College voor zorgverzekeringen, 2011; Geactualiseerde versie 2010
15. Wijnen E, Planken N, Keuter X et al. Impact of a quality improvement programme based on vascular access flow monitoring on costs, access occlusion and access failure. Nephrol Dial Transplant 2006; 21: 3514-3519
16. Manns B, Tonelli M, Yilmaz S et al. Establishment and maintenance of vascular access in incident hemodialysis patients: a prospective cost analysis. J Am Soc Nephrol 2005; 16: 201-209
17. Dutch Federation of Nephrology-Water Committee. Waterbehandeling voor hemodialyse en on-line hemo(dia)filtratie 2010, 2010. http://www.nefro.nl/ uploads/21/me/21meIoW5jeujTnCN6 oc9RQ/febr-10.RichtlijnWaterbehandeling-voor-HD- en-online HDF-2007.update-febr-2010.pdf
18. Dutch Federation of Nephrology. Richtlijn laboratoriumbepalingen bij stabiele chornische hemodialyse en peritoneale dialyse patiënten, 2010; update 2010
19. Health Care Insurance Board (CVZ). Diagnostic Compass 2003. Amstelveen: 2003
20. Hakkaart-van Roijen L. Short Form-Health and Labour Questionnaire. Institute for Medical Technology Assessment, Erasmus University Rotterdam, 2009
21. Koopmanschap MA, Rutten FF, van Ineveld BM et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171-189
22. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53-72
23. Lamers LM, Stalmeier PF, McDonnell J et al. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff. Ned Tijdschr Geneeskd 2005; 149: 1574-1578
24. van Stel HF, Buskens E. Comparison of the SF-6D and the EQ- 5D in patients with coronary heart disease. Health Qual Life Outcomes 2006; 4: 20
25. Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes 2009; 7: 27
26. Grima DT, Bernard LM, Dunn ES et al. Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs. Pharmacoeconomics 2012; 30: 981-989
27. Bobinac A, Van Exel NJ, Rutten FF et al. Willingness to pay for a quality-adjusted life-year: the individual perspective. Value Health 2010; 13: 1046-1055
28. Shiroiwa T, Sung YK, Fukuda T et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010; 19: 422-437
29. International Organization for Standardization. Guidance for the Preparation and Quality Management of Fluids for Haemodialysis and Related Therapies. Geneva: International Organization for Standardization, 2011; 23500.
30. Unruh M, Benz R, Greene T et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int 2004; 66: 355-366
31. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019
32. Organisation for Economic Co-operation and Development (OECD). OECD StatExtracts. 2011, www.oecd-ilibrary.org/statistics
33. Baboolal K, McEwan P, Sondhi S et al. The cost of renal dialysis in a UK setting-a multicentre study. Nephrol Dial Transplant 2008; 23: 1982-1989
34. Villa G, Rodriguez-Carmona A, Fernandez-Ortiz L et al. Cost analysis of the Spanish renal replacement therapy programme. Nephrol Dial Transplant 2011; 26: 3709
35. Harris A, Cooper BA, Li JJ et al. Cost-effectiveness of initiating dialysis early: a randomized controlled trial. Am J Kidney Dis 2011; 57: 707-715